October 17, 2023 11:17 AM EDT
Startups
R&D

Ul­tragenyx to spin off com­pa­ny to de­vel­op ‘high risk, high re­turn’ gene ther­a­py for Alzheimer’s dis­ease

Ayisha Sharma

News Reporter

Ul­tragenyx plans to spin off a com­pa­ny ded­i­cat­ed to de­vel­op­ing a nov­el gene ther­a­py for Alzheimer’s dis­ease that makes use of a lyso­so­mal en­zyme, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times